Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Recruiting2
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

recruiting250%
completed125%
not_yet_recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101
recruitingphase_2

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07415044
not_yet_recruitingphase_1

A Study of LY4268989 (MORF 057) in Healthy Participants

NCT07707375
completedphase_1

A Study of LY4268989 (MORF-057) in Healthy Participants

NCT06964776

Clinical Trials (4)

Showing 4 of 4 trials
NCT07186101Phase 2

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Recruiting
NCT07415044Phase 2

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Recruiting
NCT07707375Phase 1

A Study of LY4268989 (MORF 057) in Healthy Participants

Not Yet Recruiting
NCT06964776Phase 1

A Study of LY4268989 (MORF-057) in Healthy Participants

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4